The business model of Predilife SA revolves around predictive medicine and personalized healthcare solutions. Predilife SA specializes in developing innovative genetic and molecular diagnostics to detect the risk of developing different pathologies and diseases. Their advanced technology and extensive database enable them to provide accurate and early detection of health risks, allowing individuals to take proactive measures for prevention and personalized treatment. By combining scientific expertise and cutting-edge technology, Predilife SA aims to empower individuals, healthcare providers, and insurers in making informed decisions for improved health outcomes.

Predilife SA is primarily active in the healthcare and biotechnology industries. With a focus on early diagnosis and personalized medicine, Predilife SA offers innovative solutions for the detection and prevention of diseases. By leveraging advanced technologies and genetic analysis, the company aims to improve patient outcomes and reduce healthcare costs. With its expertise in predictive medicine, Predilife SA plays a vital role in the advancement of personalized healthcare and contributes to the development of innovative solutions for various medical conditions.

The main competitors of Predilife SA in the market are companies such as 1. Company Name, 2. Company Name, and 3. Company Name. These companies operate in the same industry and offer similar products/services as Predilife SA. Although Predilife SA holds a strong position in the market, it faces competition from these key players who strive to capture a share of the market. Despite the competition, Predilife SA distinguishes itself by its unique offerings, innovative solutions, and commitment to providing exceptional quality to its customers.

Predilife SA is a renowned company specializing in predictive medicine solutions. Founded in (enter founding year), Predilife has become a prominent player in the field, offering cutting-edge technologies and innovative approaches. With a strong focus on genetic testing and personalized medicine, the company aims to revolutionize healthcare by providing predictive diagnostics and risk assessments. Predilife's commitment to research, development, and collaboration has paved the way for groundbreaking advancements in predictive medicine, making them a leader in the industry. With a rich history and a commitment to improving patient outcomes, Predilife SA continues to redefine the future of healthcare.

Predilife SA, a renowned company in the stock market, has achieved remarkable milestones throughout its journey. The company's significant accomplishments include developing groundbreaking medical solutions, introducing cutting-edge technology, and gaining recognition for its exceptional scientific research. Predilife SA has successfully expanded its presence in the market, establishing itself as a leader in its field. With its consistent commitment to innovation and excellence, Predilife SA has secured numerous accolades and industry awards. The company's dedication to improving healthcare outcomes and its ability to deliver reliable and accurate results have made Predilife SA a trusted and respected name in the stock market industry.

Predilife SA is primarily present in France, Europe.

Predilife SA represents a set of values and a corporate philosophy that underscore its commitment to excellence and innovation. The company focuses on providing personalized medical solutions through highly accurate genetic tests. Predilife SA strives to empower individuals and healthcare professionals with predictive information to anticipate the risk of developing diseases. With a strong emphasis on research and development, Predilife SA aims to stay at the forefront of scientific advancements. By promoting early detection and prevention, the company values proactive healthcare and aims to improve patients' quality of life. Predilife SA's corporate philosophy revolves around personalized medicine, data-driven insights, and improving health outcomes.

Analysts currently set an average price target of 21.34 EUR for the Predilife stock (median: 21.34 EUR), implying +1,082.2 % versus the latest price. The consensus is based on 9 analyst ratings.

Predilife Analyst Price Targets 2026

9 analysts currently rate the Predilife stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Predilife to generate revenue of 1.63 M EUR and earnings per share of -1.58 EUR.

Predilife Analyst Price Targets 2026

The Predilife share (ALPRE.PA) is listed on 2 stock exchanges, including: Paris (ALPRE.PA).

Predilife SA is a company specialized in the development and sale of predictive test products. The company was founded in France in 2004 and has since become a leading provider of personalized medical services and products. The business model of Predilife SA aims to achieve better patient care and improved outcomes in the diagnosis and treatment of diseases through a range of products and medical tests. The company offers a variety of genetic tests that allow doctors and patients to predict the risk of disease before symptoms occur. The company is divided into several business areas, including genetic tests related to cardiovascular diseases, cancer, diabetes, and neurological disorders. The tests are developed and distributed by an experienced team of scientists and medical professionals to ensure that they are of the highest quality and reliability. The company also offers personalized health and nutrition counseling services to help its customers improve their long-term health and well-being. In addition, Predilife SA provides training and continuing education for medical professionals to ensure that they are informed about the latest developments and technologies in medicine and can offer their patients the best treatment options. The company aims to offer its customers personalized medical services of the highest quality at an affordable price. By partnering with hospitals, medical facilities, and private clinics worldwide, the company has established its reputation as a leading provider of personalized medical services. As part of its growth strategy, the company has expanded its portfolio of personalized medical services by developing new technologies and products to enable better diagnosis and treatment of diseases. Additionally, the company has also expanded its presence in the international market by expanding into new markets and forming partnerships with leading medical facilities. Overall, Predilife SA's business model is focused on ensuring better patient care through the development and commercialization of personalized medical services and products. The company has established itself as a trusted provider of genetic tests and personalized health and nutrition counseling services and is expected to continue expanding and growing in the future.

The expected revenue of Predilife is 1.63 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Predilife is -5.95 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Predilife is currently -1.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Predilife stock.

The price-to-sales ratio (P/S) of Predilife is currently 4.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Predilife stock.

The Eulerpool Quality Score for Predilife is 3/10.

The ISIN of Predilife is FR0010169920. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Predilife is A2PBF1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Predilife is ALPRE.PA. The ticker symbol is used to trade Predilife shares on the stock exchange.

Predilife paid dividends every year for the past 0 years.

Predilife is assigned to the 'Health' sector.

The dividends of Predilife are distributed in EUR.